Department of Medical Oncology, Dana Farber Cancer Institute, Boston, Massachusetts.
Search for other works by this author on: ...
Search for other works by this author on: ...
University of Nebraska Medical Center, Omaha, NE, ...
This open access article is distributed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0) license. This work is licensed under a Creative Commons ...
Search for other works by this author on: ...
Department of Hematology and Medical Oncology, Emory University School of Medicine, Atlanta, Georgia.
Adding the PD-1 inhibitor pembrolizumab to chemoradiotherapy for high-risk, locally advanced cervical cancer significantly improves patients’ overall survival compared to treatment with CRT alone.
Two HER2-targeted tyrosine kinase inhibitors, BAY 29270078 and zongertinib, each showed robust efficacy and safety in early phase. Patients experienced significant tumor shrinkage rates, and the ...
Program of Immunology and Immunotherapy, Cima Universidad de Navarra, Pamplona, Spain.
Copyright held by the owner/author(s).
Beginning today, the FDA requires all mammography facilities to tell patients whether they have dense breast tissue when conveying screening results. People with dense breasts have a higher risk of ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback